Get started
Author

Jumpei Okamura

Observed names: J., Okamura, Junpei Okamura, Okamura J.
ORCID: 0000-0002-3312-4128
Observed ORCID: 0000-0002-3312-4128
OpenAlex ID: A5021225592
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
2021 · Hideyuki Tamai, Jumpei Okamura · Clinical and Molecular Hepatology · 33
PDF
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease
2022 · Hideyuki Tamai, Jumpei Okamura · Hepatology Research · 10
Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
2023 · Hideyuki Tamai, Jumpei Okamura · Viruses · 8
PDF
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Journal of Gastroenterology and Hepatology · 6
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
2026 · Hideko Ohama, Atsushi Hiraoka, et al. · Hepatology Research · 6
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Liver International · 4
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
2025 · Hideyuki Tamai, Jumpei Okamura · Hepatology Research · 4
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
2026 · Atsushi Hiraoka, Toshifumi Tada, et al. · Liver Cancer · 3
PDF
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study
2023 · Hideyuki Tamai, Jumpei Okamura, et al. · Hepatology Research · 3
PDF
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
2025 · Kazuya Kariyama, Kazuhiro Nouso, et al. · Hepatology Research · 2
PDF
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
2025 · Takeshi Hatanaka, Yutaka Yata, et al. · Hepatology Research · 2
Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis
2021 · Hideyuki Tamai, Jumpei Okamura, et al. · Healthcare · 2
PDF
Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease
2025 · Hideyuki Tamai, Jumpei Okamura · Hepatology Research · 1
PDF
Effects of SGLT2 Inhibitor Therapy Combined with a Moderate-Carbohydrate Diet in Patients with MASLD
2026 · Hideyuki Tamai, Jumpei Okamura · Livers
Clinical relevance of serum full-length glypican-3 in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
2026 · Naoshi Odagiri, Masaru Enomoto, et al. · Scientific Reports
PDF
Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
2026 · Emi Tanaka, Toshifumi Tada, et al. · Oncology
Supplementary Material for: Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
2026 · figshare admin karger, Tanaka E., et al. · Figshare
Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCC
2026 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Liver International
Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma
2026 · Atsushi Hiraoka, Toshifumi Tada, et al. · Hepatology Research
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma
2026 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Hepatology International
Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
2026 · Kazuya Kariyama, Kazuhiro Nouso, et al. · Hepatology Research
Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
2026 · Kaho Aoe, Toshifumi Tada, et al. · Hepatology
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
2026 · Fujimasa Tada, Atsushi Hiraoka, et al. · Hepatology Research
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
2026 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Hepatology Research
Supplementary Material for: Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
2026 · karger, figshare admin, A., Hiraoka, et al. · Figshare
Works count: 27
Citation count: 84
H-index: 5
I10-index: 2
Year
Topic
Type